These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 31314174)

  • 1. RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes.
    Zeng RJ; Zheng CW; Gu JE; Zhang HX; Xie L; Xu LY; Li EM
    Mol Oncol; 2019 Sep; 13(9):2010-2030. PubMed ID: 31314174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA LINC00337 induces autophagy and chemoresistance to cisplatin in esophageal squamous cell carcinoma cells via upregulation of TPX2 by recruiting E2F4.
    Yang C; Shen S; Zheng X; Ye K; Ge H; Sun Y; Lu Y
    FASEB J; 2020 May; 34(5):6055-6069. PubMed ID: 32239565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of ALDH5A1 suppresses cisplatin resistance in esophageal squamous cell carcinoma by regulating ferroptosis signaling pathways.
    Song K; Ma C; Maswikiti EP; Gu B; Wang B; Wang N; Jiang P; Chen H
    Mol Carcinog; 2024 Oct; 63(10):1892-1906. PubMed ID: 38923019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma.
    Yang X; Li S; Xu C; Liu S; Zhang X; Lian B; Li M
    Cancer Biol Ther; 2024 Dec; 25(1):2365449. PubMed ID: 38865161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cucurbitacin E inhibits esophageal carcinoma cell proliferation, migration, and invasion by suppressing Rac1 expression through PI3K/AKT/mTOR pathway.
    Zhang L; Liang H; Xin Y
    Anticancer Drugs; 2020 Sep; 31(8):847-855. PubMed ID: 32568828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.
    Zuo J; Zhao M; Fan Z; Liu B; Wang Y; Li Y; Lv P; Xing L; Zhang X; Shen H
    Thorac Cancer; 2020 Mar; 11(3):738-747. PubMed ID: 32012470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotinamide N-methyltransferase decreases 5-fluorouracil sensitivity in human esophageal squamous cell carcinoma through metabolic reprogramming and promoting the Warburg effect.
    Cui Y; Yang D; Wang W; Zhang L; Liu H; Ma S; Guo W; Yao M; Zhang K; Li W; Zhang Y; Guan F
    Mol Carcinog; 2020 Aug; 59(8):940-954. PubMed ID: 32367570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin.
    Wang F; Ding X; Wang T; Shan Z; Wang J; Wu S; Chi Y; Zhang Y; Lv Z; Wang L; Fan Q
    PLoS One; 2017; 12(4):e0174276. PubMed ID: 28406985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RIT1 suppresses esophageal squamous cell carcinoma growth and metastasis and predicts good prognosis.
    Feng YF; Lei YY; Lu JB; Xi SY; Zhang Y; Huang QT; Wu QL; Wang F
    Cell Death Dis; 2018 Oct; 9(11):1085. PubMed ID: 30348939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel.
    Yan J; Shi L; Lin S; Li Y
    Bioengineered; 2021 Dec; 12(1):5334-5347. PubMed ID: 34415232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-338-5p inhibits cell proliferation, colony formation, migration and cisplatin resistance in esophageal squamous cancer cells by targeting FERMT2.
    Lin WC; Chen LH; Hsieh YC; Yang PW; Lai LC; Chuang EY; Lee JM; Tsai MH
    Carcinogenesis; 2019 Jul; 40(7):883-892. PubMed ID: 30576425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF‑α‑mediated upregulation of SOD‑2 contributes to cell proliferation and cisplatin resistance in esophageal squamous cell carcinoma.
    Zuo J; Zhao M; Liu B; Han X; Li Y; Wang W; Zhang Q; Lv P; Xing L; Shen H; Zhang X
    Oncol Rep; 2019 Oct; 42(4):1497-1506. PubMed ID: 31364751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma.
    Liu T; Li R; Zhao H; Deng J; Long Y; Shuai MT; Li Q; Gu H; Chen YQ; Leng AM
    Oncotarget; 2016 Oct; 7(41):66851-66864. PubMed ID: 27588477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1.
    Chang ZW; Jia YX; Zhang WJ; Song LJ; Gao M; Li MJ; Zhao RH; Li J; Zhong YL; Sun QZ; Qin YR
    J Exp Clin Cancer Res; 2018 Mar; 37(1):56. PubMed ID: 29530057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma.
    Lv L; Wang SC; Mo JY; Huang KL; Xu ML; Liu J
    Biochem Biophys Res Commun; 2022 Jan; 586():129-136. PubMed ID: 34839191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCT4 knockdown enhances the sensitivity of cisplatin by inhibiting glycolysis in human esophageal squamous cell carcinomas.
    Fang J; Ma Y; Li Y; Li J; Zhang X; Han X; Ma S; Guan F
    Mol Carcinog; 2022 Nov; 61(11):1043-1055. PubMed ID: 36102200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arntl-induced upregulation of DUSP1 inhibits tumor progression in esophageal squamous cell carcinoma by inactivating ERK signaling.
    Wang J; Jia Q; Sun J; Wu S; Wei L; Yao W
    Cancer Biol Ther; 2024 Dec; 25(1):2408042. PubMed ID: 39341782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entinostat reverses cisplatin resistance in esophageal squamous cell carcinoma via down-regulation of multidrug resistance gene 1.
    Huang XP; Li X; Situ MY; Huang LY; Wang JY; He TC; Yan QH; Xie XY; Zhang YJ; Gao YH; Li YH; Rong TH; Wang MR; Cai QQ; Fu JH
    Cancer Lett; 2018 Feb; 414():294-300. PubMed ID: 29107111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
    Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2.
    Zhang Z; Xiong R; Li C; Xu M; Guo M
    Acta Biochim Biophys Sin (Shanghai); 2019 Aug; 51(8):826-833. PubMed ID: 31287493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.